Simon has over 30 years of international biotech and pharma experience with leadership positions at Merck Group and Boehringer Ingelheim. He held CEO roles at several biotech companies, including Kymab (now Sanofi), and founded Ribotargets (Vernalis).

Jasper Bos, PhD is a former Merck executive and is currently General Partner at Forbion working on the firm’s Growth Fund. Before joining the Dutch company in its Naarden-based headquarters, Jasper was Senior Vice President and Managing Director at M Ventures, the venture arm of pharmaceutical giant Merck. At M Ventures, he led a team of 21 investment professionals with a fund size of EUR 400m invested in over 50 companies spanning biotech, life sciences tools, and tech companies ranging from seed-stage to cross-over and IPO. He has experience in several operational roles for portfolio companies, and played a key role in the creation of multiple successful Merck spin-out companies . Jasper holds a PhD in Pharmacy from the University of Groningen, the Netherlands.

Sabine Dandiguian is Managing Partner at Jeito Capital and has over 30 years of experience in the pharmaceutical and medical devices industry. She has in-depth operational and strategic capabilities, particularly in market access, innovative “business models” and management. Prior to Jeito, she spent 20 years at Johnson & Johnson, in operational positions of increasing responsibility in the pharmaceutical sector (Janssen) and medical devices. Her last position has been Company Group Chairman, President Europe of Johnson & Johnson’s medical. Sabine has been recognized as Chevalier de l’Ordre du Mérite, Chevalier de la Légion d’Honneur and is a member of the « Assemblée des 100 » of Institut Pasteur. She has been a member of W.I.T.H. (Women Innovating Together in Healthcare) since its creation. Sabine graduated in Finance from ESCP Business School (Grande Ecole).

Thomas Ramdahl is a pharmaceutical executive with more than 20 years of clinical and development experience. In 2001, he became President and first CEO of Algeta ASA, a Norwegian biotech company that successfully developed and launched a radiopharmaceutical for prostate cancer. Furthermore, he was instrumental in Algeta’s 2007 IPO, as well as in the acquisition of the company by Bayer AG for USD 2.9B in 2014. Dr. Ramdahl has authored more than 40 publications and is a co-inventor of several patents. He gained his PhD in environmental chemistry from the University of Oslo in 1984 and an MSc in organic chemistry from the Norwegian Institute of Technology in 1979. He has also been engaged in executive training at the International Institute for Management Development (IMD) in Lausanne, Switzerland.

Mårten Steen is Managing Partner at HealthCap. Prior to re-joining HealthCap in 2010, Dr. Steen worked with global business development at Merck Serono as a Director, focusing on both product and technology licensing. Prior to Merck Serono, he was a medical associate with HealthCap. Dr. Steen is a Medical Doctor trained at Lund University. He has pursued research in the field of protein chemistry and coagulation at Lund University and Novo Nordisk, rendering him a PhD in Clinical Chemistry in 2003. He is the author of 16 scientific papers published in peer-reviewed journals. He has also a B.Sc. degree in Business Administration from the Lund University School of Economics and Management.

Michaël Vlemmix has a background in healthcare and investment banking. Prior to joining Gimv in 2017, he was an equity analyst at KBC Securities focusing on the healthcare sector. He started his professional career at a medical device spin-off of the University of Antwerp where he also obtained a master’s degrees in bio-engineering (biotechnology) and management.

Camilla Petrycer Hansen currently serves as a principal at Novo Holdings, where she focuses on company creation and early-stage investments. She is also part of the investment team in the REPAIR Impact Fund. She is a member of the Board of Directors of Hoba Therapeutics and Centauri Therapeutics and also acts as an observer on the Boards of Directors for Muna and Hemab. Camilla previously worked in various business development roles spanning positions at early-stage to commercial-stage companies (e.g., Novozymes, Statens Serum Institute (SSI) and Wake Forest University Health Sciences in the United States). She holds a PhD in Medicinal Chemistry and a Master of Pharmacy from Copenhagen University.

Ivan serves as a Junior Partner on Inkef's Healthcare team, having joined in January 2019 following the completion of his MBA from INSEAD. With a background in biological science and a PhD in Genetics, he brings a decade of experience in applied and fundamental research. Before joining Inkef, Ivan worked in strategy and business development roles at Sanofi, advised startups in biotechnology and digital health, and interned at Forbion Capital Partners.

Emily Tow Chair in Oncology at Memorial Sloan Kettering Cancer Center (MSK)

Vice Chair for Research and Chief Attending of the Radiochemistry & Imaging Sciences Service in MSK’s Department of Radiology

Laboratory Head in the Sloan Kettering Institute’s Molecular Pharmacology Program

Dr. Lewis is an expert in the field of molecular imaging and the development of radiopharmaceuticals for the diagnosis and treatment of cancer. He has published over 350 papers, books, book chapters, and reviews in the field of cancer imaging. He earned a B.Sc. in Chemistry and a M.Sc. in Chemistry from the University of Essex. He obtained a Ph.D. in Biochemistry from the University of Kent and was a postdoctoral researcher at the Washington University School of Medicine (WUSM). He subsequently joined the WUSM faculty as an Assistant Professor at the Mallinckrodt Institute of Radiology. In 2008 he joined MSKCC, where he is a Member. He is also a Professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences and at Weill Cornell Medical College.

Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center

Associate Director of Precision Oncology at the Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine

Founding Director of the Michels Rare Cancers Research Laboratories

Dr. Razelle Kurzrock, a leader in precision medicine and the development of novel cancer therapies, has been listed as one of the most important voices in precision medicine and is on the Web of Science list of most cited scientists globally. She has over 950 peer reviewed publications and has been principal investigator for over 100 early phase clinical trials, including early trial of 8 FDA-approved drugs. She is the Chair for the Early Therapeutics and Rare Cancers Committee (SWOG NCI), and along with the DART rare cancer study team, received the National Cancer Institute Director’s Award of Merit for Outstanding Work. Previously, she was Director of both the Center for Personalized Cancer Therapy and the Experimental Therapeutics Program, and Founder of the Rare Tumor Clinic at Moores Cancer Center at UC San Diego Health. Dr. Kurzrock is recognized for founding, developing and chairing one of the largest Phase 1 clinical trial departments globally while at the University of Texas MD Anderson Cancer Center. She has held Board positions in the National Comprehensive Cancer Network (NCCN), and currently is on the Board of the SWOG Cancer Research Network and WIN Consortium in cancer personalized medicine. She has an MD from the University of Toronto, and completed a Residency in Internal Medicine at Tulane University Hospital, and a Fellowship in Medical Oncology at MD Anderson.

Research Director, Team Leader at the French National Institute for Health and Medical research (INSERM)

Dr. Jean-Pierre Pouget obtained his PhD in Radiobiology from the Curie Institute in Paris and performed a post-doctoral fellowship at the Nuclear Medicine Research Laboratory at Barts and the London School of Medicine and Dentistry. He then joined the French Radiation Protection and Nuclear Safety Agency (IRSN) and subsequently the French National Institute for Health and Medical research (INSERM) where he now is team leader of the Radiobiology and Targeted Radiotherapy group at the Cancer Research Institute of Montpellier. Dr. Pouget’s research focuses on the development of new radiopharmaceuticals for cancer imaging and therapy, unravelling the role of targeted (radiative) and non-targeted (bystander and systemic) effects of molecular radiotherapy involving intercellular communications and/or the involvement of the immune system. He has published more than 90 papers and book chapters on topics in radiobiology and radionuclide therapy and several patents.

Professor of Radiology and Radiological Science at Johns Hopkins University

Director Radiological Physics Division at the Department of Radiology and Director of Radiopharmaceutical Dosimetry at Johns Hopkins University

Dr. Sgouros received his undergraduate degree in applied physics from Columbia University. He obtained his PhD from Cornell University and performed a fellowship in medical physics at Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center in New York, where he was Associate Professor. Dr. Sgouros is a Member of the Johns Hopkins Kimmel Cancer Center. His research focuses on modeling and dosimetry of internally administered radionuclides with a particular emphasis on patient-specific dosimetry, alpha-particle dosimetry, and mathematical modeling of radionuclide therapy. Dr. Sgouros chaired multiple committees, including the SNMMI MIRD Committee, an ICRU Committee on dosimetry for radiopharmaceutical therapy, an NIH grant review panel and most recently, organized RPT-TEC (RPT-Tissue Effects in the Clinic) to help consolidate dose-response data for radiopharmaceutical therapeutics.

James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy at Hoag Family Cancer Institute, Professor of Radiology and Translational Genomics, University of Southern California

Dr. Ulaner is a recognized expert in the use of targeted imaging to help direct focused cancer therapies; he is dual-board certified in radiology and nuclear medicine. He completed his medical degree and Ph.D. in Cancer Biology at Stanford University School of Medicine, an internship at Johns Hopkins Hospital, and his Radiology and Nuclear Medicine residencies at the University of Southern California. Before joining Hoag, he served as the PET/CT expert on the Breast Cancer and Myeloma Disease Management Teams of the Memorial Sloan Kettering Cancer Center. Today, Dr. Ulaner leads several National Institutes of Health (NIH) clinical trials in molecular imaging and therapeutics. Dr. Ulaner has authored or co-authored more than 150 peer-reviewed manuscripts, has given more than 200 national and international presentations and wrote a textbook on the fundamentals of oncologic PET/CT.